Form 4 for URGN UroGen Pharma Ltd.
Accepted 2022-01-07 00:00:00 ET · period of report 2022-01-03 · accession 0001209191-22-002305 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-07 | 2022-01-03 | URGN | Barrett Elizabeth A. | CEO | M - OptEx | — | +105.7K | 345.2K | +44% | — |
| D | 2022-01-07 | 2022-01-04 | URGN | Barrett Elizabeth A. | CEO | S - Sale+OE | $9.15 | -47.0K | 298.2K | -14% | -$429.8K |
| D | 2022-01-07 | 2022-01-03 | URGN | Barrett Elizabeth A. | CEO | M - OptEx | $0.00 | -105.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-01-03 | M | A | 105,689 | — | 345,188 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer |
| 2 | Common | Ordinary Shares | 2022-01-04 | S | D | 46,968 | $9.15 | 298,220 | D | — | — | (F2) Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units |
| 3 | Derivative | Restricted Stock Units | 2022-01-03 | M | D | 105,689 | $0.00 | 0 | D | — · — to — | 105,689 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer (F3) The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs vested on January 3, 2022. |